Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Biologics
•
Pulmonology
•
Obstructive Lung Disease
•
Asthma
What is your approach to switching from one biologic agent to another in allergic asthma/type II inflammation?
Related Questions
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
Is methacholine challenge on its way out?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Do you use hypercapnia as an exclusion criteria in all patients that are being assessed for bronchoscopic lung volume reduction?
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
Do you utilize the bronchiectasis severity index (BSI) in your approach to managing non-CF bronchiectasis?
Do you use continuous or intermittent bronchodilator therapy in severe airway obstruction?
How do you approach initiation/continuation of biologics if there is a suspicious pulmonary nodule that requires close interval imaging (i.e every 3 or 6 months)?
Are the results of the BOREAS trial generalizable to non-white populations?
